Skip to content

OPA Annual Conference

Learn more about this year's networking and CE opportunities!

OPA_AC27_banner

2027 OPA Annual Conference

Friday, April 16, 2027 | 7:30 AM - 6:15 PM
McMenamins Kennedy School

Day
Hour
Minute
Second

Registration Fees

 

OPA Member Registration

Life & Honorary Member Registration

Student Registration

Non-Member Registration

Early Bird Registration through
January 16th

$200

$175

$50

$275

Registration Beginning on
January17th

$225

$200

$50

$300

Schedule At a Glance

Time

7:30 AM - 8:30 AM

8:30 AM - 9:45 AM

9:45 AM - 10:00 AM

10:00 AM - 11:15 AM

11:15 AM - 11:30 AM

11:30 AM - 12:45 PM

12:45 PM - 2:15 PM

2:15 PM - 3:15 PM

3:15 PM - 3:30 PM

3:30 PM - 5:30 PM

 

5:30 PM - 6:15 PM

6:00 PM - 7:00 PM

CEU's

-

1

-

1

-

1

-

1

-

2

Agenda Item

Registration Opens & Breakfast

CE Session - TBI Topic

Networking Break

CE Session - Prolonged Exposure

Networking Break

CE Session - Suicide Intervention

Lunch & Student Presentations

OBOP Town Hall

Networking Break

Psilocybin and Mental Health: What the Research Says and What It Means for Oregon Psychologists

OPA Networking Reception

Optional Dinner with the OPA Board - Space Limited $30/Ticket

Session Information

Oregon Board of Psychologists (OBOP) Panel

Representatives from the Oregon Board of Psychology (OBOP) will provide important updates on licensure, rules, and regulatory expectations affecting the practice of psychology in Oregon. This session offers attendees the opportunity to stay informed on compliance requirements, recent changes, and best practices for maintaining ethical and professional standards.

Psilocybin and Mental Health: What the Research Says and What It Means for Oregon Psychologists

Oregonians engage with psilocybin primarily through three routes. First, in clinical trials, psilocybin is being studied as a treatment, typically paired with some form of psychological support. Second, Oregon Psilocybin Services (OPS), the state’s legal psilocybin program, gives adults access outside a medical setting. Third, and most commonly, people use psilocybin outside regulated settings. Recent research indicates that Oregon adults report past-year hallucinogen use at about twice the national rate and that much of the state’s recent rise in psilocybin use is happening outside licensed service centers. This two-hour workshop reviews what the research shows and what it means for clients and patients engaging with psilocybin through any of these routes. We begin with the current evidence on psilocybin, including clinical trial outcomes, proposed mechanisms, potential benefits, and known risks. We then review where psilocybin stands in the FDA approval process and what approval could mean for psychologists in Oregon. Next, we explain how OPS works and how psychologists can engage with it. Finally, we provide guidance for working with clients and patients who are considering or currently using psilocybin, whether through OPS or outside the regulated system, including how to discuss their use and recognize when an outside referral may be helpful. Throughout, we offer practical strategies for well-informed conversations about psilocybin, along with the ethical and legal considerations relevant to Oregon psychologists. The workshop is designed for psychologists in any setting and at any level of familiarity with psychedelics.

Learning Objectives

Participants will be able to:

  1. Describe the current state of research on psilocybin, including the conditions with the strongest evidence and key limitations of existing studies.
  2. Identify the primary risks, adverse events, and contraindications associated with psilocybin use.
  3. Describe the options for accessing psilocybin in Oregon, including Oregon Psilocybin Services and psilocybin-assisted therapy, and how they differ.
  4. Discuss clinically, ethically, and legally appropriate ways to respond to clients/patients who are considering or have used psilocybin, including when an outside referral may be helpful.
Jason Headshot

Jason Luoma, Ph.D., is CEO of Portland Psychotherapy in Portland, OR. His research focuses on shame, self-stigma, connection, self-compassion and the application of ACT and psychedelic assisted therapy to shame and self-criticism. He has been an investigator on three clinical trials of psychedelics (MDMA-AT for social anxiety, 5-MO-DMT for treatment resistant depression, and psilocybin-assisted therapy for chronic pelvic pain), as well as more than two decades of research resulting in over 75 peer-reviewed publications relating to psychology, psychedelics, and psychotherapy. He is a peer-reviewed trainer in Acceptance and Commitment Therapy (ACT), has delivered more than 200 workshops and trainings throughout the world, and contributed to the development of the association for Contextual Behavioral Science including serving as president. Dr. Luoma is co-author of two books including one of the best-selling ACT books for therapists, Learning ACT: An Acceptance and Commitment Therapy Skills Training Manual for Therapists, as well as Values in Therapy: A Clinician’s Guide to Helping Clients Explore Values, Increase Psychological Flexibility, and Live a More Meaningful Life. He is also an innovative leader who has created numerous organizations and initiatives, including being co-founder and CEO of Portland Psychotherapy Clinic, Research, & Training Center, a social enterprise that funds psychological research through profits obtained through a group clinical practice and co-founder of the Open Psychedelic Evaluation Nexus, an interdisciplinary research network studying the impact of state legal psychedelic services. He is also co-Founder of Perspectives Retreats, an organization that provides experiential training retreats for health care providers wanting to gain experience with psychedelic-assisted therapy. He is also senior scientist at the Portland Institute for Psychedelic Science and host of The Research Matters Podcast, a podcast that interviews leaders and experts in psychological research.   His work on shame and compassion can be read at www.actwithcompassion.com.

Jenna Headshot

Jenna LeJeune, Ph.D. is President and co-founder of Portland Psychotherapy Clinic, Research and Training Center in Portland, Oregon. She is also a therapist at the Portland Institute for Psychedelic Science where she is involved in various clinical trials involving psychedelic-assisted psychotherapy. As a clinical psychologist, Dr. LeJeune is deeply interested in issues of meaning, purpose, and values. Much of her work focuses on working with shame, sexuality, and relationship struggles, including an individual’s relationship with their own body. She is the co-author of the book Values in Therapy: A Clinician's Guide to Helping Clients Explore Values, Increase Psychological Flexibility, and Live a More Meaningful Life as well as numerous other book chapters, journal articles, and other publications. Dr. LeJeune is also a peer-reviewed ACT trainer and provides ACT trainings for professionals around the world.

Scroll To Top